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Chronic kidney disease in sub-Saharan Africa: 
a public health priority
In 2008, the World Health Assembly endorsed the Global 
Noncommunicable Disease Action Plan amid growing 
evidence that  NCDs have replaced communicable disease 
as the most common cause of premature mortality 
worldwide.1 Chronic kidney disease (CKD), a non-
communicable disorder included in the plan, is ranked 
18th among the global causes of death—it was ranked 
27th in 1990, and the number of deaths from CKD has 
risen by 82% during that time.2 It is the third largest 
increase among the top 25 causes of death, behind HIV/
AIDS (396%) and diabetes (93%).2
In the adult US population the estimated prevalence 
of CKD stage 1–4 is 11·6% (about 26 million people),3 
a ﬁ gure similar to that reported in other high-income 
countries, such as Norway (10·2%), Japan (12·7%), 
Taiwan (11·8%), China (10·7%), and South Korea 
(13·7%).4 Less information, however, is available from 
low-to-middle-income countries, where prevalence of 
mild-to-moderate CKD is variable but generally lower 
than 20% of the total adult population.4 Even more 
scarce are CKD data from very poor regions, such as sub-
Saharan Africa. 
In The Lancet Global Health, John Stanifer and 
colleagues assessed the largely sparse and anecdotal 
information about the epidemiology of CKD in 
sub-Saharan Africa in their systematic review and 
meta-analysis.5 Only 21 of the retrieved 90 articles 
were regarded as suitable for the analysis (being of 
medium-to-high quality), eventually providing data 
for only 13 of 47 countries in the region. Most of the 
44 145 studied individuals were younger than the 
age at which renal function naturally declines, with a 
mean age ranging from 35 years to 46 years. With this 
background and the limitation of data missing for most 
countries, the overall prevalence of CKD in the region 
was 13·9% (95% CI 12·2–15·7), with estimates ranging 
from 2% in Cote d’Ivoire to 30·2% in Zimbabwe, and 
approaching 20% in Ghana, Nigeria, Rwanda, and 
DR Congo. Between-country diﬀ erences in reported 
data are largely a result of the unavailability of blood 
or dipstick urine tests to diagnose kidney disease, 
even though they are very simple or inexpensive. 
The diagnosis of CKD is therefore easily missed. 
Estimated CKD prevalences could also simply depend 
on between-country diﬀ erences in CKD deﬁ nition and 
populations screened. Therefore, ﬁ rm conclusions about 
CKD prevalence in the region cannot be reached, but the 
true burden is probably high. 
In their analysis, the investigators did not include 
common causes of CKD in sub-Saharan Africa other than 
HIV, diabetes, and hypertension—notable omissions 
were chronic glomerulonephritis and use of herbal or 
traditional treatments. Also, communicable diseases 
might contribute substantially to CKD burden in low-
income countries. For example, in several resource-poor 
regions worldwide, tuberculosis—which often causes 
irreversible renal destruction—is endemic.6 Community 
screening programmes in Mongolia and Nepal have 
shown that more than 40% of people with CKD did 
not have diabetes or hypertension.7 Moreover, data 
from Nepal and Bolivia showed that more than 5% of 
people younger than 60 years without previous history 
of diabetes and hypertension had microalbuminuria or 
proteinuria.8 Together, these ﬁ ndings indicate that, in 
low-income countries, glomerulonephritis and CKD of 
unknown origin might account for a larger proportion 
of the total CKD burden. Considering that the prevalence 
of diabetes and high blood pressure is also progressively 
increasing in resource-poor countries, it should be 
assumed that the CKD burden will become even higher 
in regions such as sub-Saharan Africa than in high-
income countries. 
The broad message from Stanifer and colleagues’ 
study draws attention to three important areas that 
should be considered when developing an approach 
to renal disease in sub-Saharan Africa. An urgent 
requirement exists for health information systems 
to capture data to better measure the incidence and 
prevalence of renal failure, track patient outcomes, 
establish the true burden of disease, and assess access 
to and quality of nephrology services. At the same time, 
eﬀ orts to increase awareness about kidney disease and 
its complications in communities and among many 
physicians should be pursued because many are not 
aware of the severity of this disorder, which probably 
serves as a barrier to appropriate care of patients even 
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where available. More importantly, the development of 
speciﬁ c national health policies for the early detection 
and treatment of kidney disease are needed, including 
policies to strengthen laboratory infrastructures to 
improve accuracy of diagnosis. Besides saving young 
lives, such action would create major health gains 
and minimise the present health inequity that arises 
mainly from the unaﬀ ordable cost of renal replacement 
therapy if end-stage kidney disease is not prevented.
Norberto Perico, *Giuseppe Remuzzi
IRCCS—Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, 
Italy (NP, GR); and Unit of Nephrology and Dialysis, Azienda 
Ospedaliera Papa Giovanni XXIII, Bergamo, Italy (GR)
giuseppe.remuzzi@marionegri.it
We declare that we have no competing interests.
Copyright © Perico et al. Open Access article distributed under the terms of 
CC BY-NC-ND
1  WHO. Preventing chronic disease: a vital investment. Geneva: World Health 
Organization, 2005.
2  Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality 
from 235 causes of death for 20 age groups in 1990 and 2010: 
a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012; 380: 2095–128.
3  Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of 
chronic kidney disease to the global burden of major noncommunicable 
diseases. Kidney Int 2011; 80: 1258–70.
4  Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: 
global dimension and perspectives. Lancet 2013; 382: 260–72.
5  Stanifer JW, Jing B, Tolan S, et al. The epidemiology of chronic 
kidney disease in sub-Saharan Africa: a systematic review and 
meta-analysis. Lancet Global Health 2014; published online Feb 10. 
http://dx.doi.org/10.1016/S2214-109X(14)70002-6.
6  Eastwood JB, Corbishley CM, Grange JM. Tuberculosis and the kidney. 
J Am Soc Nephrol 2001; 12: 1307–14.
7  Sharma SK, Zou H, Togtokh A, et al. Burden of CKD, proteinuria, and 
cardiovascular risk among Chinese, Mongolian, and Nepalese participants 
in the International Society of Nephrology screening programs. 
Am J Kidney Dis 2010; 56: 915–27.
8  Cravedi P, Sharma SK, Bravo RF, et al. Preventing renal and cardiovascular 
risk by renal function assessment: insights from a cross-sectional study in 
low-income countries and the USA. BMJ Open 2012; 2.
